Meng-Ning Wei
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism
- Oncology top 10%
- Drug Transport and Resistance Mechanisms
Papers in
-
- Cancer therapeutics and mechanisms 3
- CRISPR and Genetic Engineering 3
- Oncology 8
- Drug Transport and Resistance Mechanisms 4
- Colorectal Cancer Treatments and Studies 2
- Cancer Treatment and Pharmacology 2
- Co-authors
- Zhi Shi (22 shared papers)Qiwei Jiang (17 shared papers)Zihao Xing (12 shared papers)Jia-Rong Huang (14 shared papers)Di-Wei Zheng (9 shared papers)Wenji Zhang (9 shared papers)Wu-Ming Qin (7 shared papers)Youqiu Xue (4 shared papers)
- Journals
- Frontiers in Oncology (6 papers)Cancer Letters (2 papers)Oncotarget (2 papers)Frontiers in Pharmacology (2 papers)Scientific Reports (1 paper)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Meng-Ning Wei
23 papers receiving 764 citations
Peers
Comparison fields: 5 of 87
- Cancer Research 215
- Oncology 233
- Complementary and alternative medicine 66
- Toxicology 27
- Molecular Biology 512
Countries citing papers authored by Meng-Ning Wei
This map shows the geographic impact of Meng-Ning Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meng-Ning Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meng-Ning Wei more than expected).
Fields of papers citing papers by Meng-Ning Wei
This network shows the impact of papers produced by Meng-Ning Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meng-Ning Wei. The network helps show where Meng-Ning Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Meng-Ning Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 107 | |
| 2 | Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. | 2015 | 78 |
| 3 | 2017 | 64 | |
| 4 | 2015 | 61 | |
| 5 | 2015 | 56 | |
| 6 | Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing. | 2016 | 45 |
| 7 | 2019 | 44 | |
| 8 | 2020 | 33 | |
| 9 | 2021 | 33 | |
| 10 | 2018 | 32 | |
| 11 | 2016 | 31 | |
| 12 | 2019 | 28 | |
| 13 | Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo. | 2018 | 26 |
| 14 | 2019 | 25 | |
| 15 | 2018 | 21 | |
| 16 | 2020 | 17 | |
| 17 | 2019 | 15 | |
| 18 | Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer. | 2017 | 15 |
| 19 | 2019 | 13 | |
| 20 | YM155 enhances docetaxel efficacy in ovarian cancer. | 2018 | 12 |
About Meng-Ning Wei
Meng-Ning Wei is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Surgery, having authored 23 papers that have together received 770 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (4 papers), Drug Transport and Resistance Mechanisms (4 papers), Cancer therapeutics and mechanisms (3 papers), Cancer-related molecular mechanisms research (3 papers), CRISPR and Genetic Engineering (3 papers), Colorectal Cancer Treatments and Studies (2 papers), Cancer Treatment and Pharmacology (2 papers) and Natural Compounds in Disease Treatment (2 papers). The work is most often cited by research in Cancer Research (215 citations), Oncology (233 citations), Complementary and alternative medicine (66 citations), Toxicology (27 citations) and Molecular Biology (512 citations). Meng-Ning Wei has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Zhi Shi, Qiwei Jiang, Zihao Xing, Jia-Rong Huang, Di-Wei Zheng, Wenji Zhang, Wu-Ming Qin, Youqiu Xue, Yao Li and Xiao-Long Mei. Their work appears in journals such as Frontiers in Oncology, Cancer Letters, Oncotarget, Frontiers in Pharmacology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.